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Introduction
Plant alkaloids are a highly diverse group of natural compounds containing a ring structure and one or more basic nitrogens. Alkaloids have often marked pharmacological activity and plants containing alkaloids have traditionally been used as a source of medicinal products all around the world. Some alkaloids have been successfully developed into widely used pharmaceuticals e.g. morphine, codeine, apomorphine, papaverine, emetine and noscapine (Gotti, 2011; Newman and Cragg, 2012; Hagel and Facchini, 2013) .
Natural herbal products, including Traditional Chinese Medicine (TCM) preparations, are becoming more and more popular also in Western countries (Gotti, 2011; Salminen et al., 2011b; Pelkonen et al., 2014) . It is often claimed that herbal medicines are harmless because of their natural origin and long-term use. Nevertheless, it is evident that these products can cause a variety of adverse effects (Izzo and Ernst, 2009; Jordan et al., 2010; Singh et al., 2012) , and may elicit numerous clinically significant drug interactions (Tsai et al., 2012) .
Human liver cytochrome P450 (P450) enzymes metabolize a very large variety of compounds including many synthetic and natural medicines (Wienkers and Heath, 2005; Guengerich, 2008) .
Although the CYP2C19 enzyme catalyzes the metabolism of fewer drug substrates than other enzymes in its family, e.g. CYP3A4 and CYP2D6 enzymes, it plays an important role in the metabolism of some proton pump inhibitors, antidepressants, antipsychotics, antiepileptics and antiplatelet drugs (Rendic, 2002; Pelkonen et al., 2008; Wang et al., 2009) . In fact, the popular platelet antagonist clopidogrel is a prodrug activated by CYP2C19 (Scott et al., 2013) .
Inhibition of P450 enzymes is a major mechanism for pharmacokinetic drug interactions (Wienkers and Heath, 2005; Boobis et al., 2009) . In general, P450 enzymes are inhibited either as reversible inhibition or via the more profound and prolonged irreversible or quasi-irreversible inactivation. Irreversible or quasi-irreversible mechanism-based (i.e. P450 catalysis-dependent) inactivation is of greater practical concern due to its serious risk of causing clinically significant drug interactions. Time-dependent inhibition (TDI) is one of the major features which distinguishes between reversible inhibition and irreversible or quasi-irreversible mechanismbased inactivation.
Several components in herbal medicines have been shown to inhibit various members of the P450 enzyme family (Izzo and Ernst, 2009; Posadzki et al., 2013) . The methylenedioxyphenyl (MDP) moiety is present in many plant compounds, including alkaloids; these secondary metabolites are intended to deter the foraging by predatory insects and herbivores (Murray, 2012) . There are reports that compounds containing the MDP moiety can inactivate P450 enzymes due to the formation of a metabolite intermediate complex (MIC) with the enzyme, leading to quasiirreversible enzyme inactivation (Casida, 1970; Franklin, 1971; Nakajima et al., 1999; Correia and Ortiz de Montellano, 2005) . With the increasing popularity of herbal medicinal products, human exposure to plant compounds with the MDP moiety may become significant.
Drug interaction potential is today routinely screened during the drug development process. We have previously evaluated the inhibitory characteristics of several natural and chemically derived isoquinoline alkaloids towards all of the principal human drug metabolizing P450
enzymes. Many alkaloids proved to be potent inhibitors of the CYP2C19, CYP2D6 and CYP3A4
forms, and three of them (protopine, bulbocapnine and canadine) were identified as mechanismbased inactivators of CYP2C19 (Salminen et al., 2011b; Salminen et al., 2011c) . Although several mechanism-based inactivators have been identified for P450s, very few attempts have been made to evaluate these compounds by exploiting molecular modeling (in silico) approaches.
Several quantitative structure-activity relationship (QSAR) models have been published for CYP2C19 ligands (Suzuki et al., 2002; Lewis, 2004; Suzuki et al., 2004; Lewis et al., 2006; Gleeson et al., 2007; Foti et al., 2012) , but thus far, none have specifically addressed mechanismbased inactivators.
In this study, we evaluated putative interactions of structurally related isoquinoline alkaloids with the CYP2C19 enzyme using in vitro and in silico approaches. Special attention was paid to the inhibition of CYP2C19 by alkaloids containing the MDP moiety. Molecular modeling, including docking and a 3-dimensional quantitative structure-activity relationship (3D-QSAR) analysis, was conducted to devise a model for prediction of inhibitory activity of alkaloids.
Materials and Methods
Chemicals. The isoquinoline alkaloids 1-8, 10-17, 20-39 have been described in our previous studies (Meyer and Imming, 2011; Salminen et al., 2011b) Inhibition of CYP2C19 activity. The IC 50 values for the alkaloids were determined essentially as described previously (Salminen et al., 2011a; Salminen et al., 2011b) . In short, the assay procedure was used in two steps. First four to five different concentrations (mainly 1:10 ratio) of each alkaloid at a concentration range of 0.05 µM to 1000 µM (water soluble compounds up to 6.67 mM) was used for prescreening. After that a more precise concentration range (seven different concentrations, mainly 1:3 ratio) was used inthe kinetic assay procedure without substrate premeasurement. In the standard preincubation assay, a mixture containing the inhibitor, enzyme (1.5 pmol), and a NADPH-regenerating system was first preincubated for 30 min at 37°C, after which the reactions were initiated by the addition of the substrate at a concentration corresponding to its apparent K m (1 µM DBF). The IC 50 values were compared to those obtained in similar experimental conditions without preincubation (Salminen et al., 2011b (Salminen et al., 2011c) . The progress curve analysis assay was performed in duplicate for compounds 2, 14, 17, 22, 27, 31, 33, 34, 37, 38, and 39. The curves were visually inspected to determine whether a compound exhibited time-and concentration-dependent inhibition. The known time-dependent CYP2C19 inhibitor isoniazid and the known reversible inhibitor tranylcypromine were used as positive controls.
Molecular Modeling
Structure preparation. The crystal structure of human CYP2C19 with the inhibitor 2-methyl-1-benzofuran-3-yl)-(4-hydroxy-3,5-dimethylphenyl)methanon (PDB: 4GQS) (Reynald et al., 2012) was used for molecular docking studies. The protein structure was processed with the Protein Preparation Wizard of Schrödinger Maestro v. 9.6 (Schrödinger, 2013) using standard settings (add hydrogens, assign bond orders, create zero order bonds to metals and disulfide bonds and delete waters beyond 5 Å from heteroatoms). Hydrogen bonds were assigned and the prepared structure was minimized using OPLS_2005 force field and restrained minimization (heavy atom converging RMSD 0.30 Å). The missing side chains were added to the crystal structure using Prime version 3.0 (Schrödinger, 2012a) .
The crystal structures for the following alkaloids were retrieved from the Cambridge Structural Database (CSD) using ConQuest program (Allen, 2002; Bruno et al., 2002) : 4 (reference code 9 pH 7 ± 1 using Epik and all possible enantiomers (or a maximum of 32) were created if chirality was not present in the original structures.
Molecular docking. Glide version 5.8 Halgren et al., 2004; Friesner et al., 2006; Schrödinger, 2012b ) was used to dock alkaloids in the active site of CYP2C19. The Glide grid-file was constructed to represent the shape and properties of the crystal structure of CYP2C19 (PDB: 4GQS) in order to provide more accurate scoring of the ligands. The center of the grid was defined based on the co-crystallized ligand (2-methyl-1-benzofuran-3-yl)-(4-hydroxy-3,5-dimethylphenyl)methanon) of CYP2C19to determine the position of the active site.
A sufficiently large grid of 20 Å in length was defined to ensure that there is enough space for large ligands. The metal coordination constraint of heme iron as well as the positional constraints that define the spherical region occupied by inhibitors were applied. These constraints were used to ensure that the ligands were orientated close to the heme. The flexible docking studies were carried out for all alkaloids. The docking results were visually inspected, and the highest scoring docking poses in which MDP moiety is orientated close to the heme iron were chosen for 3D-QSAR evaluation using the Comparative Molecular Field Analysis (CoMFA) method with Sybyl-X 2.0 (Cramer et al., 1988; Tripos, 2011) .
CoMFA models. Molecular docking was used to align 49 alkaloids in the conformation shown in the crystal structure of 4GQS. The alkaloids were divided to a training set (1-8, confirmed to demonstrate TDI of CYP2C19 activity. The known time-dependent inhibitor isoniazid and the known reversible inhibitor tranylcypromine were used as control compounds.
As expected, upon preincubation the IC 50 of isoniazid was reduced up to 10-fold and that of tranylcypromine was unaffected or increased up to 2-fold.
The most potent CYP2C19 inhibition was exhibited by the protopine, protoberberine, and phthalideisoquinoline alkaloids. In contrast, none of the aporphine alkaloids displayed evidence of potent inhibition ( Table 1 ). The most potent inhibitor was dihydroprotopine 8, which had an IC 50 value of 0.11 µM. Other potent inhibitors (IC 50 <1 µM) were compounds 3 (cryptopine), 6
(corycavamine), 7 (dihydrocryptopine), 17 (capnoidine), 19 (noscapine), 20 (canadine), 21
(nandinine), and 25 (stylopine).
The moderately potent inhibitors (IC 50 1-10 µM) were compounds 1 (protopine), 10 (apomorphine), 12 (bulbocapnine), 15 (nantenine), 16 (parfumine), 22 (corydaline), 23
(tetrahydropalmatine), 24 (corypalmine), 26 (thalictricavine), 28 (corybulbine), 35 (2,3-dimethoxy-10,11-methylenedioxyberbine), 36 (2,3-dimethoxy-9,10-methylenedioxyberbine), 38
(3-methoxyberbine), 45 (chelidonine), and 46 (papaverine). The progressive scrambling analysis indicated three components as being optimal based on the minimum value for cSDEP with maximum q 2 value (Supplementary Material Table S3 
All of the potent inhibitors (IC
Discussion
The present results provide information about 1) the potential of a series of plant alkaloids to interfere with metabolism of drugs metabolized by CYP2C19, and 2) the interaction of these ligands with the active site of the CYP2C19 enzyme.
Several (9/49) of the studied alkaloids were found to be potent time-dependent inhibitors of CYP2C19 (IC 50 <1 µM). In this study, the presence of the MDP moiety increased the inhibitory potency. The IC 50 shift assay is a straightforward and widely used test to detect TDI while the progress curve analysis method has been more recently applied for P450s (Berry and Zhao, 2008; Salminen et al., 2011a; Stresser et al., 2014) . Using these approaches, most of the studied alkaloids (42/49) demonstrated time-and concentration-dependent inhibition. The MDP moiety of most of the alkaloids was coordinated towards the heme. Three TCM compounds with MDP, protopine (1), bulbocapnine (12), and canadine (20) were shown to cause quasi-irreversible inactivation of CYP2C19 mediated via MIC formation in our previous study (Salminen et al., 2011c) . These compounds contain a MDP moiety orientated towards the heme in the CYP2C19 active site in the present molecular docking analysis.
We made a detailed search from the commercial TCM Database: Traditional Chinese Medicines:
Molecular Structures, Natural Sources and Applications (NiceData, 2005 For example, noscapine (19), a phthalideisoquinoline alkaloid isolated from opium and widely used as an antitussive drug, has been associated with serious drug interactions when coadministered with warfarin (Ohlsson et al., 2008; Scordo et al., 2008; Fang et al., 2010) . It has been demonstrated to inhibit CYP2C9 and CYP3A4 in vitro in a time-dependent fashion (Fang et al., 2010) . In an in vivo study, noscapine caused marked inhibition of CYP2C9 and CYP2C19
activity (Rosenborg et al., 2010) . The potent inhibition (IC 50 0.2 µM), the presence of TDI and noscapine's orientation in the active site of CYP2C19 observed in the present study are consistent with the proposal that this drug possesses the ability to affect the CYP2C19 pathway in vivo.
Two moderately potent TCM alkaloids, chelidonine (45, IC 50 1.4 µM), used as a cancer chemotherapeutic drug (Panzer et al., 2001) , and papaverine (46, IC 50 of 2.2 µM), used for treatment of vasospasm (Komotar et al., 2007) , may also have the capability to affect the CYP2C19-mediated metabolism of other drugs. Based on the present data, two TCM compounds, the non-inhibitor berberine (43, IC 50 150 µM) and the weak CYP2C19 inhibitor sinomenine (47, IC 50 55 µM), are unlikely to affect the metabolism of drugs that are substrates of CYP2C19.
Berberine (43) has been extensively studied and it is a widely used constituent in herbal products (Vuddanda et al., 2010; Guo et al., 2012) . The observed low CYP2C19 inhibitory potency (IC 50 150 µM) is consistent with previous in vitro (Han et al., 2011) and in vivo studies in humans (Guo et al., 2012) . Sinomenine (47) arrhythmia. Previously, it has been reported that sinomenine has inhibited the activity of CYP2C19 in human microsomes, and in an in vivo study at normal clinical doses, sinomenine has enhanced the elimination of mephenytoin, a marker of CYP2C19 activity (Yao et al., 2007) .
Molecular docking and predictive CoMFA models were generated to pinpoint steric and electrostatic interactions between the alkaloids and the CYP2C19 active site. Molecular docking is a common approach used to predict the bioactive conformation to generate CoMFA models (Rahnasto et al., 2011) . Different types of constraints are often employed to improve the docking into the P450 enzymes (Rahnasto et al., 2011) . Here, the alkaloids were docked into the X-ray structure of CYP2C19 as it has been observed that a 3D-QSAR model based on X-ray structure can achieve a much better performance and improved statistical significance (Urniaz and Jozwiak, 2013). The CoMFA steric and electrostatic field maps of the alkaloids were consistent with the crystal structure of CYP2C19 active site.
The progressive scrambling method was applied to address possible overly optimistic crossvalidation (Clark and Fox, 2004) . A QSAR model is considered to be predictive if the following conditions are satisfied: r 2 > 0.6, q 2 > 0.5 (Golbraikh et al., 2003) . According to these criteria, the present CoMFA model (r 2 = 0.9 and q 2 = 0.6) has a high goodness-of-fit, robustness and 1 8
In conclusion, we identified several plant alkaloids containing the MDP moiety to be potent timedependent inhibitors of the CYP2C19 enzyme. Molecular docking and 3D-QSAR analysis revealed key interactions between the alkaloids and the CYP2C19 active site. A CoMFA model was constructed which was capable of predicting inhibition potency. These results suggest that clinically significant drug interactions could well occur when some of these alkaloids are used concomitantly with drugs metabolized by CYP2C19. This study highlights that when further refined, in silico methods will provide rapid and reliable tools for predicting the propensity of any xenobiotics to inhibit P450 mediated metabolism. Table S1 . Statistical values of the CoMFA models. CoMFA models were developed based on docking alignment of alkaloids. The models were validated using leave-one-out (LOO). -7-methyl-9,10-dimethoxy-5,6,7,8,13,14-hexahydrodibenzo [d,h,] 
